ADHD Drug Medication Guide On Potential Cardiac Risks Recommended By Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Drug Safety & Risk Management Advisory Committee recommended that the agency issue a medication guide for attention deficit/hyperactivity disorder drugs on potential cardiovascular risks of the stimulant class; committee splits on “black box” warning for ADHD drugs.
You may also be interested in...
ADHD Black Box Warning On Psychiatric/Cardiac Events Is Unnecessary, Pediatric Committee Says
FDA’s Pediatric Advisory Committee recommends adding regular warnings on possible psychosis, aggression, and cardiovascular risks to all attention deficit/hyperactivity disorder drugs.
ADHD Black Box Warning On Psychiatric/Cardiac Events Is Unnecessary, Pediatric Committee Says
FDA’s Pediatric Advisory Committee recommends adding regular warnings on possible psychosis, aggression, and cardiovascular risks to all attention deficit/hyperactivity disorder drugs.
Cephalon Looks To Q2 For Launch Of Sparlon
Cephalon has pushed back the anticipated launch of its attention deficit/ hyperactivity disorder drug Sparlon (modafinil) from Q1 until the second quarter, pending the outcome of a review by FDA's Psychopharmacologic Drugs Advisory Committee March 23